Autoimmune Disease Diagnostics Market Overview

The global autoimmune disease diagnostics market size is expected to reach USD 8.20 billion by 2030, registering a CAGR of 6.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government organizations along with related associations strive to curb such high healthcare costs and simultaneously provide improved diagnostic and therapeutic solutions to the patients. This has resulted in increased funding by the NIH for RD programs related to autoimmune diseases.

Moreover, the presence of favorable government initiatives aimed at curbing the incidence of these diseases and developing viable diagnostic treatment options is expected to drive market growth over the forecast period.

Growing volume of autoimmune diagnostic procedures has heightened the need for instruments and facilities rendering faster and effective results. In an attempt to cater to ever-increasing procedure volumes, diagnostic laboratories are rapidly moving toward automation. Lab automation helps decrease workload via rapid turnaround times and helps generate standardized reproducible results.

Autoimmune Disease Diagnostics Market Report Highlights

• The localized autoimmune disease diagnostics segment dominated the market and accounted for a revenue share of 64.7% in 2023.
• The consumables assays segment accounted for the largest revenue share in 2023. Every laboratory diagnostic test utilizes test kits, reagents, and antibodies.
• In terms of test type, antinuclear antibody tests (ANA) accounted for a leading market share in 2023. The growth of this segment is attributed to affordability, high sensitivity, and extensive availability.
• The hospitals segment accounted for the largest revenue share in 2023. The high share is attributed to the increased adoption of autoimmune disease diagnostic practices in hospitals for various diseases.
• The North America autoimmune disease diagnostics market dominated the global industry and accounted for a revenue share of 42.8% in 2023. The Asia Pacific autoimmune disease diagnostics market is anticipated to witness a fastest CAGR from 2024 to 2030.

Autoimmune Disease Diagnostics Market Segmentation

Grand View Research has segmented global autoimmune disease diagnostics market report based on type, product, test, end-use, and region:

Autoimmune Disease Diagnostics Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Systemic autoimmune disease diagnostics
  • Rheumatoid arthritis
  • Ankylosing spondylitis
  • Systemic lupus erythematosus (SLE)
  • Others
• Localized autoimmune disease diagnostics
  • Multiple sclerosis
  • Type 1 diabetes
  • Hashimoto's thyroiditis
  • Idiopathic thrombocytopenic purpura
  • Others

Autoimmune Disease Diagnostics Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Instruments
• Consumables and Assays

Autoimmune Disease Diagnostics Test Outlook (Revenue, USD Billion, 2018 - 2030)

• Antinuclear antibody tests
• Autoantibody tests
• C-reactive Protein (CRP)
• Complete blood count (CBC)
• Urinalysis
• Others

Autoimmune Disease Diagnostics End-use Outlook (Revenue, USD Billion, 2018 – 2030)

• Hospitals
• Clinical Laboratories
• Others

Autoimmune Disease Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
• South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • Saudi Arabia
  • UAE
  • South Africa
  • Kuwait

Key Players in the Autoimmune Disease Diagnostics Market

• Hoffmann-La Roche Ltd
• Siemens Healthineers
• EUROIMMUN Medizinische Labordiagnostika AG
• Quest Diagnostics
• Abbott
• Danaher Corporation
• BIOMÉRIEUX
• INOVA DIAGNOSTICS
• Hemagen Diagnostics, Inc.
• Beckman Coulter, Inc.

Order a free sample PDF of the Autoimmune Disease Diagnostics Market Intelligence Study, published by Grand View Research.